Ambrisentan for pulmonary arterial hypertension

Area of Science:

• Pharmacology
• Cardiology
• Pulmonology

Background:

• Pulmonary arterial hypertension (PAH) requires effective treatments.
• Endothelin receptor antagonists (ERAs) are a key therapeutic class for PAH.
• Ambrisentan is an investigational ERA with specific characteristics.

Purpose of the Study:

• To evaluate the efficacy and safety of ambrisentan in patients with PAH.
• To assess ambrisentan's impact on functional capacity and hemodynamics.
• To determine the tolerability and adverse event profile of ambrisentan.

Main Methods:

• Phase II clinical study design.
• Assessment of 6-minute walk distance, Borg dyspnea index, and WHO Functional Class.
• Hemodynamic measurements and liver function tests.

Main Results:

• Ambrisentan improved key clinical endpoints including walk distance and dyspnea.
• The drug demonstrated good tolerability with no dose-related adverse events.
• Low incidence and severity of liver function abnormalities were observed.
• No significant interactions with cytochrome P450 isoenzymes were identified.

Conclusions:

• Ambrisentan is a well-tolerated, selective endothelin type-A receptor antagonist for PAH.
• Its oral, once-daily dosing and favorable safety profile offer potential advantages.
• Reduced risks of liver toxicity and drug-drug interactions compared to other ERAs.